ADIL earnings date and last-quarter result: next report 2026-08-12, last quarter beat, P/E -0.28. Updated 2026-07-23.
Adial Pharmaceuticals (ADIL) Research Hub
Adial Pharmaceuticals (ADIL) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 3.68 USD (-6.12%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.28, market cap 0.00B. This hub links to the full technical, earnings and options research available for ADIL.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 3.68 USD (-6.12%) |
| 52-week range | 2.33 USD – 7.2 USD |
| Trend regime | Range |
| 14-day RSI | 44.6 (Bearish) |
| Trailing P/E | -0.28 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for ADIL
Covered Call on ADIL: how it works, illustrative setup around the real 3.68 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on ADIL: how it works, illustrative setup around the real 3.68 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on ADIL: how it works, illustrative setup around the real 3.68 USD price, max profit/loss, breakeven and when to use it. Educational.
ADIL technical analysis: range, last 3.68 USD, RSI 44.6, 52w range 2.33 USD–7.2 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is ADIL in?
Adial Pharmaceuticals (ADIL) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is ADIL in an uptrend or downtrend?
As of 2026-10-26, ADIL is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is ADIL's trailing P/E ratio?
ADIL's trailing P/E is -0.28, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does ADIL next report earnings?
ADIL is next scheduled to report earnings on 2026-08-12.